Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil
Carregando...
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Citação
ATHEROSCLEROSIS, v.277, p.273-277, 2018
Resumo
Background and aims: Familial hypercholesterolemia (FH) is a genetic disorder associated with high cardiovascular burden of disease. FH prevalence may vary widely across populations and data in race/ethnically diverse and admixed populations is scarce. ELSA-Brasil epidemiology may be widely generalizable in this regard, and we calculated the ELSA-Brasil FH prevalence and its variation according to age, sex and race/ethnicity. Methods: In 14,460 individuals aged from 35 to 75 years from the ELSA-Brasil cohort baseline, we classified FH according to the Dutch Lipid Clinic Network criteria score >= 6 (probable and definite FH). LDL-C levels were adjusted for statin use. We calculated the overall ELSA-Brasil FH prevalence and the weighted prevalence for age, sex and race/ethnic categories. We extrapolated those frequencies to the Brazilian population weighting for age-sex-race/ethnicity according to the 2015 Statistics and Geography Brazilian Institute survey. Results: The overall FH prevalence per 1000 individuals in ELSA-Brasil was 3.8 (2.9, 4.9) or 1 in 263. The age/sex/race-ethnicity-weighted FH prevalences were: male, 3.0 (1.7, 4.4) or 1 in 333; female, 4.1 (3.0, 5.2) or 1 in 244 (p<0.001). White race prevalence was 2.4 (1.9, 3.0) or 1 in 417; Brown, 4.9 (4.0, 5.9) or 1 in 204; and Black 6.4 (41.1, 8.7) or 1 in 156 (p<0.001). The weighted extrapolation for the Brazilian population derived similar magnitude frequencies. Conclusions: FH affects 1 in 263 in ELSA-Brasil and affects disproportionally more Brown (1 in 204), and Black (1 in 156), than White (1 in 417). Weighted extrapolation for the Brazilian population derived similar magnitude frequencies.
Palavras-chave
Familial hypercholesterolemia, Prevalence, Sex, Race, Ethnicity, Epidemiology
Referências
- Akioyamen LE, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016461
- [Anonymous], 1995, RES POP PERC DISTR A
- Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
- Benn M, 2016, EUR HEART J, V37, P1384, DOI 10.1093/eurheartj/ehw028
- Benn M, 2012, J CLIN ENDOCR METAB, V97, P3956, DOI 10.1210/jc.2012-1563
- Bensenor IM, 2013, REV SAUDE PUBL, V47, P37, DOI 10.1590/S0034-8910.2013047003780
- Besseling J, 2016, J AM COLL CARDIOL, V68, P252, DOI 10.1016/j.jacc.2016.04.054
- de Ferranti SD, 2016, CIRCULATION, V133, P1067, DOI 10.1161/CIRCULATIONAHA.115.018791
- Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
- GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332
- Hopkins PN, 2011, J CLIN LIPIDOL, V5, pS9, DOI 10.1016/j.jacl.2011.03.452
- Lotufo PA, 2016, J CLIN LIPIDOL, V10, P568, DOI 10.1016/j.jacl.2015.12.029
- Mangili LC, 2016, ATHEROSCLEROSIS, V254, P73, DOI 10.1016/j.atherosclerosis.2016.09.010
- Mark DB, 2017, JAMA-J AM MED ASSOC, V318, P711, DOI 10.1001/jama.2017.8907
- Sabatine M. S., 2017, N ENGL J MED, V376
- Santos RD, 2015, LANCET, V385, P307, DOI 10.1016/S0140-6736(14)61702-5
- Silva PRS, 2017, ATHEROSCLEROSIS, V263, P257, DOI 10.1016/j.atherosclerosis.2017.06.917
- Talmud PJ, 2013, LANCET, V381, P1293, DOI 10.1016/S0140-6736(12)62127-8
- Watts GF, 2007, NAT CLIN PRACT CARD, V4, P404, DOI 10.1038/ncpcardio0941
- Zamora A, 2017, J CLIN LIPIDOL, V11, P1013, DOI 10.1016/j.jacl.2017.05.012